TABLE 4.
Laboratory and CT findings of eight COVID-19 cases before and after QFPDD treatment.
| Variables | Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | Case 6 | Case 7 | Case 8 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 0 | Day 6 | Day 0 | Day 6 | Day 0 | Day 6 | Day 0 | Day 6 | Day 0 | Day 6 | Day 0 | Day 6 | Day 0 | Day 6 | Day 0 | Day 6 | |
| Laboratory findings | ||||||||||||||||
| NEU, ×109/L (2.5–7.5) | 0.57 (↓) | 3.93 | 5 | 4 | 6.96 | 3.6 | 18.01 (↑) | 9.62 (↑) | 2.31 (↓) | 5.3 | 2.38 (↓) | 4.65 | 6.28 | 2.21 (↓) | 5.99 | 4.72 |
| LY, ×109/L (0.8–4.0) | 1.51 | 1.18 | 1.6 | 2.2 | 1.42 | 0.63 (↓) | 0.66 (↓) | 1.01 | 0.73 | 0.95 | 1.17 | 2.23 | 0.50 (↓) | 1.16 | 1.2 | 1.27 |
| WBC, ×109/L (4.0–10.0) | 6.67 | 6.03 | 7.1 | 6.8 | 9.25 | 5.67 | 19.07 (↑) | 11.23 (↑) | 3.3 (↓) | 7 | 3.90 (↓) | 7.64 | 7.6 | 4.37 | 7.8 | 6.73 |
| PLT, ×109/L (100–350) | 155 | NR | 279 | 221 | NR | 170 | 143 | NR | 124 | 278 | 202 | 304 | 199 | 449 (↑) | 276 | 251 |
| AST, U/L (15–40) | 18 | 17 | 16 | 15.3 | 19.8 | 16.4 | 30.5 | 23.4 | 39.2 | 36.2 | 39 | 21 | 11 (↓) | 18 | 18 | 19 |
| ALT, U/L (0–40) | 14 | 15 | 15 | 15 | 27.7 | 20.3 | 19 | 23.9 | 7.2 | 11.2 | 29 | 31 | 21 | 22 | 16 | 20 |
| ALP, U/L (female: 50–135; male: 45–125) | 80.1 | 87.4 | 47.0 (↓) | 54.9 | 78.3 | 77.1 | 52.4 | 47.7 | 38.9 (↓) | 42.8 (↓) | 43 (↓) | 54 | NR | NR | 56 | 70 |
| CK, U/L (18.0–198.0) | 78 | 137 | NR | 77.8 | NR | NR | 120.5 | NR | 225 | 133 | 97 | 38 | NR | NR | 25 | 26 |
| CK-MB, U/L (0–18) | 32 (↑) | 10 | NR | NR | NR | NR | 14 | NR | 0.9 | 1.2 | 10 | 8 | NR | NR | 8 | 10 |
| LDH, U/L (135.0–215.0) | 166 | NR | 143 | 153.4 | NR | NR | 254 (↑) | NR | 781 (↑) | 681 (↑) | 376 (↑) | 205 | 326 (↑) | NR | 161 | 168 |
| UREA, mmol/L (2.9–7.5) | 7.76 (↑) | 8.96 (↑) | 4.6 | 5.22 | NR | NR | 4.36 | NR | 4.2 | 3.6 | 6.09 | 4.55 | 8.30 (↑) | 5.8 | 5.16 | 5.06 |
| CREA, mmol/L (female: 44–97; male: 54–106) | 72.9 | 83.2 | 57 | 59.8 | NR | NR | 72.9 | NR | 77 | 78 | 72.4 | 57.4 | 75 | 77 | 61 | 61 |
| PCT, mg/L (<0.5 mg/L) | 0.1 | 0.23 | 0.064 | NR | NR | NR | 0.04 | NR | 0.05 | <0.05 | 0.22 | NR | 0.06 | 0.05 | NR | NR |
| ESR, mm/60 min (female: 0–20; male: 0–15) | 12 | 12 | 44 (↑) | 38 (↑) | NR | NR | NR | NR | NR | NR | 42 (↑) | NR | 40 (↑) | NR | NR | NR |
| CRP, mg/L (0.068–8.2) | <5 | NR | 18.12 (↑) | 7.44 | NR | 2.9 | 31.92 (↑) | NR | 0.85 | 1.25 | 40.3 (↑) | NR | 10 (↑) | 5 | 10.94 (↑) | 4.9 |
| CT funding | ||||||||||||||||
| No abnormal lesions | Yes | Yes | No | No | No | No | No | No | No | No | No | No | No | No | No | No |
| Unilateral lung injury | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No |
| Bilateral lung injury | No | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
↑: higher than normal, ↓: lower than normal.
NR indicates not record data.
Neutrophil count (NEU), lymphocyte count (LY), white blood cell count (WBC), platelet count (PLT), aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatine kinase (CK), creatine kinase isoenzyme (CK-MB), alkaline phosphatase (ALP), lactate dehydrogenase (LDH), urea nitrogen (UREA), serum creatinine (CREA), procalcitonin (PCT), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) levels.